KRKim Rajappan

Kim Rajappan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kim Rajappan has a total of 246 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Late Gadolinium Enhancement and Recovery of Left Ventricular Function After Catheter Ablation for Atrial Fibrillation

    by Sayed Al-Aidarous, Saffron Rajappan, Zhen Hua, Ayesha Ahmed, Rohan Patel, Christopher Patrick Uy, Matthew Webber, Mahmoud Elmowafy, Nikhil Ahluwalia, Sofiane Kouadria, et al.

    Lay Summary: Atrial fibrillation (AF) is an abnormal heart rhythm that can weaken the heart’s pumping function, resulting in heart failure. Catheter ablation is a procedure used to treat AF, in which thin tubes are passed through the blood vessels to the heart to target the areas responsible for the abnormal rhythm. In some patients with AF and heart failure, ablation can allow heart function to recover. However, it remains difficult to predict which patients will benefit most. Magnetic resonance imaging (MRI) of the heart can identify areas of damaged heart muscle, often referred to as scar or fibrosis. The pattern of scar is often used to help identify the cause of heart failure, and previous studies have shown that patients with scar are less likely to have improvement in heart function. In this study, we assessed 134 patients with AF and heart failure who underwent MRI before catheter ablation. We examined whether scar was present, its location and pattern, and how much of the heart muscle was affected. Overall, 101 patients had meaningful improvement in heart function after ablation. Patients who did not improve had approximately twice as much scar as those who did. Scar pattern or location did not predict recovery, but the amount of scar did. This suggests that clinicians should consider the amount of scar, rather than its presence or pattern alone, when estimating recovery after ablation. Even when MRI suggests another cause of heart failure, AF may still be contributing and patients may still benefit from ablation.

  • Sinus rhythm duration after direct current cardioversion for persistent atrial fibrillation and long-term outcomes after subsequent catheter ablation

    by Pok-Tin Tang, Alexandre Almorad, Giampaolo Vetta, Jia H Chan, Jonathan Hampshire, Kate Eastwick-Jones, Holden Eaton, Calum A Robertson, Rebecca L M Griffiths, Amanda Hurst, et al.

    Background Patients undergoing catheter ablation (CA) for persistent atrial fibrillation (PsAF) experience high rates of AF recurrence. Direct current cardioversion (DCCV) is often performed prior to CA, with variable post-DCCV duration of sinus rhythm (SR). Objective We aimed to determine whether shorter SR duration after DCCV is associated with AF recurrence after subsequent CA. Methods We performed an international multicentre retrospective study of patients undergoing first-time CA for PsAF between 2015 and 2024 with a prior DCCV. SR duration after the last DCCV preceding CA was recorded. The primary outcome was freedom from atrial arrhythmia after CA (after a 56-day postablation blanking period). Results 938 patients undergoing first-time CA for PsAF were identified from six centres and categorised by post-DCCV SR duration: 31 days (group 3, n=490). Over median post-CA follow-up of 511 days, 512 patients (55%) experienced atrial arrhythmia recurrence. There was no significant between-group difference in freedom from atrial arrhythmia (log-rank p=0.10). When analysed as a continuous variable in a Cox regression model, there was no association between post-DCCV SR duration and time to first recurrence of atrial arrhythmia (HR per 10-day increment 1.00, 95% CI 1.00 to 1.01, p=0.07). In secondary analyses, there were significantly more blanking period arrhythmias in groups 1 and 2 compared with group 3 (both pairwise pConclusion In this large multicentre cohort, shorter duration of SR after DCCV was associated with blanking period arrhythmia after subsequent CA, but we did not find evidence of an association with long-term AF recurrence. Clinicians should consider these findings when making decisions regarding suitability for CA or predicting long-term CA success.

  • Open Access

    Kidney disease increases the risk of cardiovascular events in patients with device-detected atrial fibrillation: NOAH-AFNET 6

    by Andreas Goette, Marc D Lemoine, Alexander Fierenz, Emanuele Bertaglia, Vincent Beuger, Carina Blomstrom-Lundqvist, Axel Brandes, Melanie Calvert, A John Camm, Gregory Chlouverakis, et al.


  • Open Access

    Integrated Cardiac and Circulating N-glycan Signatures Reflect Atrial Remodeling in Patients with Atrial Fibrillation

    by Chi Him Kendrick Yiu, Jack Cheeseman, Georgia Elgood-Hunt, Chenhan Sam Ma, Abhirup Banerjee, Lucia M. Moreira, Aaron Michael Johnston, Neelam Mehta, Kathryn Cox, Timothy R. Betts, et al.

    Background: Atrial adverse remodeling drives the maintenance and progression of atrial fibrillation (AF) through electrical and structural myocardial changes, often accompanied by inflammation. Circulating N-glycans are emerging as biomarkers in inflammatory diseases, yet their role in AF remains undefined. Methods: We profiled the serum N-glycome of 138 patients with AF, non-AF arrhythmias, or sinus rhythm (SR) controls from peripheral venous (PV) and coronary sinus (CS) samples using hydrophilic interaction liquid chromatography coupled with high-resolution mass spectrometry. Glycan traits associated with AF were identified via logistic regression adjusted for clinical risk factors. Multivariate glycan scores were derived from PV and CS datasets using LASSO regression. In a subset (N=37), plasma proteome profiling was performed with the Olink Reveal panel. Results: Sixty-two glycan peaks were detected; 27 in PV and 8 in CS serum differed significantly between AF and controls. PV and CS glycan scores accurately classified AF, with the PV score correlating with 11 plasma proteins linked to structural remodeling and thrombo-inflammatory processes. The most abundant glycan, A2G2S2 (peak 30), was associated with higher odds of AF after adjusting for confounders (OR 2.22 [95% CI: 1.40–3.75], P = 0.001). CS A2G2S2 correlated with C-reactive protein (R = 0.432, P = 0.0275) and was elevated in patients with left atrial enlargement (P = 0.0354), but unchanged in those with impaired left ventricular ejection fraction or hypertrophy. Conclusion: Integrated profiling of peripheral and cardiac serum identifies novel N-glycosylation signatures in AF. Specific cardiac and circulating N-glycan signatures, including A2G2S2, are associated with AF and reflect inflammation-driven atrial remodeling, highlighting potential mechanistic pathways and biomarker applications.

  • Open Access

    The Changing Landscape of Cardiac Electrophysiology

    by Pouyan Razminia, Prateeth Pati, Peter Brady, Mahfuzur Rahman, Kim Rajappan, Rajesh Rajan

  • Safety and Feasibility of Magnetic Resonance Imaging Within the First Week Following Transvenous Pacing System Implantation

    by Jonathan Raby, Benjamin Bussmann, Pok-Tin Tang, C. Fielder Camm, Dimitrios Panagopoulos, Hongyan Tao, Jennifer J. Rayner, Timothy R. Betts, Matthew Ginks, Julian Ormerod, et al.

  • Open Access

    Effects of anticoagulation in patients with device-detected atrial fibrillation and multiple stroke risk factors: a win ratio analysis of the NOAH-AFNET 6 trial

    by Nina Becher, Gina Köllner, Emanuele Bertaglia, Carina Blomstrom-Lundqvist, Axel Brandes, Vincent Beuger, Melanie Calvert, A John Camm, Nuno Cabanelas, Gregory Chlouverakis, et al.

    Aims: Patients with device-detected atrial fibrillation (DDAF) have a lower stroke risk than those with ECG-diagnosed AF, requiring careful evaluation of oral anticoagulation benefits vs. its inherent bleeding risk. Methods and results: An unmatched win ratio analysis was performed of the NOAH-AFNET 6 trial dataset, using components of the primary efficacy and safety outcomes of the trial. The primary analysis used this hierarchical order: (1) all-cause death, (2) stroke, (3) systemic or pulmonary embolism/myocardial infarction, and (4) major bleeding. Two additional analyses replaced all-cause death with cardiovascular death or included patient-reported outcomes. Win odds were calculated to account for undecided comparisons. Among 2534 patients 77 ± 7 years old, 947 (37%) women, median CHA2DS2-VA score 3 [interquartile range (IQR), 3–4], median follow-up 21 months (IQR, 10–38) 1 605 280 win ratio pairs were analyzed. The win ratio comparing edoxaban to no anticoagulation was 0.87 (95% CI: 0.68–1.10; P = 0.23). Most comparisons resulted in no clear winner (undecided pairs 84.9%). In the remaining comparisons, edoxaban won in 46% of the cases, placebo in 54%. Death and major bleeding were the most common events. The win odds was 0.98 (95% CI: 0.94–1.01; P = 0.23). Conclusions: This hypothesis-generating win ratio analysis, integrating death, thrombotic events, and major bleeds with and without quality of life, did not find an advantage of anticoagulation with edoxaban over no anticoagulation in patients with DDAF. The most common events were death and major bleeding.


  • Open Access

    Withdrawing guideline-directed medical therapy after left ventricular ejection fraction recovery following atrial fibrillation ablation: a multicentre cohort study

    by Sayed Al-Aidarous, Saffron Rajappan, Nikhil Ahluwalia, Christopher P Uy, Hatem Abdelgawad, Caterina Vidal Horrach, Sofiane Kouadria, Zhen Hua, Gurkiran Sandhar, Theo Cooke, et al.

    Background: Atrial fibrillation (AF)-induced cardiomyopathy (AIC) is characterised by reversible left ventricular (LV) dysfunction after restoration of sinus rhythm (SR). The need for continued guideline-directed medical therapy (GDMT) for heart failure after LV ejection fraction (LVEF) recovery in AIC after catheter ablation (CA) is unclear. Methods: This multicentre cohort study across 12 UK centres included adults undergoing index AF ablation (June 2019–June 2024) with LVEF <50% preablation and recovery to ≥50% at three timepoints: preablation; early postablation (≥4 weeks) and late postablation (≥3 months or ≥3 months post-GDMT withdrawal). Patients were stratified post recovery of LVEF after CA. The primary outcome was mean LVEF at late follow-up; secondary outcomes included absolute change in LVEF, LV end-diastolic diameter (LVEDD) and SR maintenance. Results: 88 patients met inclusion enrolment criteria (61.7±10.6 years old; 91% male), of which 50 (56.8%) continued full-dose GDMT and 38 (43.2%) withdrew ≥50% of GDMT. In the GDMT-withdrawn group, mean GDMT classes decreased from 2.97±0.88 to 1.03±0.79 (p0.8). SR was maintained in 82.0% vs 92.1% of patients; p=0.17. Conclusions: Selective GDMT withdrawal after sustained LVEF recovery and rhythm control did not compromise LV systolic function, remodelling or rhythm maintenance. This supports the study of personalised de-escalation strategies in AIC in prospective trials.


  • Open Access

    Education of healthcare professionals to improve guideline adherence in atrial fibrillation: the STEEER-AF cluster-randomized clinical trial

    by Dipak Kotecha, Karina V. Bunting, Samir Mehta, Philipp Sommer, Maciej Sterliński, Kim Rajappan, Lluís Mont, Eduard Guasch, Serge Boveda, Giuseppe Boriani, et al.

    Guideline-adherent care is associated with better patient outcomes, but whether this can be achieved by professional education is unclear. Here we conducted a cluster-randomized controlled trial across 70 centers in six countries to understand if a program for the education of healthcare professionals could improve patient-level adherence to clinical practice guidelines on atrial fibrillation (AF). Each center recruited patients with AF seen in routine practice (total N = 1,732), after which the centers were randomized, accounting for baseline guideline adherence to class I and III recommendations from the European Society of Cardiology on stroke prevention and rhythm control. Healthcare professionals in the intervention centers received a 16-week structured educational program with an average of 9 h of online engagement, whereas those at control centers received no additional education beyond standard practice. For the co-primary stroke prevention outcome, guideline adherence was 63.4% and 58.6% at baseline and 67.5% and 60.9% at 6–9-months follow-up for the intervention and control groups, respectively (adjusted risk ratio 1.10; 95% confidence interval (CI) 0.97 to 1.24; P = 0.13). For the co-primary rhythm control outcome, guideline adherence was 21.4% and 20.4% at baseline and 33.9% and 22.9% at follow-up for the intervention and control groups, respectively (adjusted risk ratio 1.51; 95% CI 1.04 to 2.18; P = 0.03). The secondary outcome of patient-reported integrated AF management showed a 5.1% improvement in the intervention group compared with the control group (95% CI 1.4% to 8.9%; P = 0.01). Thus, while the education of healthcare professionals improved substantial gaps in implementation for rhythm control, it had no significant effect on stroke prevention. ClinicalTrials.gov registration: NCT04396418.


  • Open Access

    Primary care assessment of transient loss of consciousness in adults

    by Connor Thorn, Thomas Round, Kim Rajappan, Nicholas R Jones

    First, the clinician should try to establish whether a patient truly lost consciousness. A collateral history from a witness or video evidence is often vitally important to understand features of the event and duration of syncope. It may be necessary to ask patients if the clinician can ring friends and family to obtain this information. If an event was unwitnessed, TLoC should be suspected where a patient has a memory gap around a fall. When in doubt, it should be assumed that the patient had TLoC until proven otherwise.